Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters


  • Tyler L. Quest, BS
  • Joseph O. Merrill, MD
  • John Roll, PhD
  • Andrew J. Saxon, MD
  • Roger A. Rosenblatt, MD, MPH




buprenorphine, opioid dependence, rural physicians


Background: The introduction of buprenorphine as office-based treatment for opioid dependence was designed to expand treatment capacity, but virtually there are no data about use of this medication in rural areas.
Methods: The survey of the first cohort of physicians in rural Washington State who obtained buprenorphine waivers (2002-2010) to determine the volume of treated patients, physician appraisal of the efficacy of this treatment, and perceived barriers to treatment was conducted. Twenty-four (73 percent) of the 33 rural buprenorphine-certified physicians practicing in the state were interviewed in 2010.
Results: Twenty physicians (83 percent) were actively prescribing buprenorphine/naloxone for treatment of addiction. Those currently prescribing averaged 23 active patients and had treated 125 patients since certification. All respondents reported that buprenorphine was efficacious in the treatment of addiction and 95 percent recommended that other rural colleagues adopt buprenorphine treatment. The following four major barriers were cited: 1) lack of adequate financial support from Medicaid, the largest source of third-party coverage for these patients; 2) unavailability of local mental health and behavioral addiction treatment services; 3) difficulty in finding consultants to assist in managing complex patients; and 4) shortages of other rural physicians providing this service.
Conclusions: Buprenorphine is viewed as a highly effective treatment of opioid addiction by early adopters in rural Washington State, but relatively few rural physicians currently provide this service. Inadequate insurance coverage, a shortage of effective links with consultants and colleagues, and the lack of mental health services are persistent barriers to the use of this modality in rural Washington State.

Author Biographies

Tyler L. Quest, BS

Department of Family Medicine, University of Washington School of Medicine, Seattle, Washington.

Joseph O. Merrill, MD

Department of Medicine, Division of General Internal Medicine, University of Washington School of Medicine, Seattle, Washington.

John Roll, PhD

Director, Program of Excellence in the Addictions, Washington State University School of Nursing, Spokane, Washington.

Andrew J. Saxon, MD

Department of Psychiatry and Behavioral Sciences, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System, University of Washington School of Medicine, Seattle, Washington.

Roger A. Rosenblatt, MD, MPH

Department of Family Medicine, University of Washington School of Medicine, Seattle, Washington.


Centers for Disease Control and Prevention (CDC): Overdose deaths involving prescription opioids among Medicaid enrollees–Washington, 2004-2007. Morb Mortal Wkly Rep. 2009; 58: 1171-1175.

Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363: 1981-1985.

Fiellin DA: Buprenorphine: Effective treatment of opioid addiction starts in the office. Am Fam Physician. 2006; 73: 1513-1514.

Jaffe JH, O’Keeffe C: From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003; 70: S3-S11.

Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992; 267: 2750-2755.

Fiellin DA, O’Connor PG: Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347: 817-823.

Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949-958.

Arfken CL, Johanson CE, di Menza S, et al.: Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat. 2010; 39: 96-104.

Lenardson J, Race M, Gale JA: Availability, Characteristics, and Role of Detoxification Services in Rural Areas [working paper #41]. Portland, ME: University of Southern Maine, Maine Rural Health Research Center, 2009.

Substance Abuse & Mental Health Services Administration: Buprenorphine Physician and Treatment Program Locator. 2010. Available at http://buprenorphine.samhsa.gov/bwns_locator/. Accessed March 21, 2011.

Hailu A, VanEenwyk J: Guidelines for Using Rural-Urban Classification Systems for Public Health Assessment. Olympia, WA: Washington State Department of Health, 2009. Available at http://www.doh.wa.gov/data/guidelines/RuralUrban1.htm. Accessed March 1, 2010.

Kennedy J, Dipzinski A, Roll J, et al.: Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011; 114(2-3): 201-206.

Knudsen HK, Abraham AJ, Johnson JA, et al.: Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009; 37: 307-312.

Meier BR, Patkar AA: Buprenorphine treatment: Factors and first-hand experiences for providers to consider. J Addict Dis. 2007; 26: 3-14.

Thomas CP, Reif S, Haq S, et al.: Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv. 2008; 59: 909-916.

Fordyce MA, Chen FM, Doescher MP: 2005 Physician Supply and Distribution in Rural Areas of the United States. Seattle, WA: WWAMI Rural Health Research Center, University of Washington, 2007.

Yen W: Washington State’s Practicing Physician Workforce–Capacity and Characteristics. Washington State Health Services Research Project. Research Brief No. 058. Olympia, WA: Washington State Office of Financial Management, 2010.

Ducharme LJ, Abraham AJ: State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008; 3: 17.



How to Cite

Quest, BS, T. L., J. O. Merrill, MD, J. Roll, PhD, A. J. Saxon, MD, and R. A. Rosenblatt, MD, MPH. “Buprenorphine Therapy for Opioid Addiction in Rural Washington: The Experience of the Early Adopters”. Journal of Opioid Management, vol. 8, no. 1, Jan. 2012, pp. 29-38, doi:10.5055/jom.2012.0093.